Guest guest Posted July 13, 1999 Report Share Posted July 13, 1999 Hey Cheryl, How you feeling? Missed hearing from you.....funny the documents that Kay sent came through great on my Microsoft Internet Outlook express mail program....I especially love the picture of Steere....do you or anyone know how I can blow that baby up???? I want to work out some rage? Hugs, Marta >From: cheryl@... > >Hi. I am in digest mode and was unable to read your attachments. Do you think you could either repost them as regular text, or send them to me privately? > >There was a post titled " dear dr. steere " and another about ebola virus. > >) >Cheryl (LI, NY) > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 14, 1999 Report Share Posted July 14, 1999 Natural Antibody, Recombinant IgG Effectively Neutralize Ebola Virus -------------------------------------------------------------------------------- By Saunders WESTPORT, Jul 06 (Reuters Health) - A neutralizing human antibody to Ebola virus has been identified by a US team of researchers, who also generated a recombinant IgG molecule that may be useful in passive prophylaxis against infection. Dr. Dennis R. Burton, of The Scripps Research Institute in La Jolla, California, used RNA from survivors of a 1995 Ebola virus outbreak in the Congo to construct phage display libraries of monoclonal antibodies. These were panned with Ebola virus antigens--nucleoprotein, envelope glycoprotein, and soluble envelope glycoprotein. The investigators identified seven reacting antibodies. The recombinant fragment (Fab) of one of them, an antibody specific for envelope glycoprotein, " ...neutralized Ebola virus to 50% at 0.4 mcg/mL. " When this Fab was expressed as a whole IgG protein, antiviral activity was improved, with 50% neutralization occurring at a concentration of 0.3 mcg/mL. Dr. Burton and colleagues note that this neutralizing potency " ...is within the range that may lead to protection in passive-immunization studies. " Immunoglobulin concentrations that produce 90% neutralization have been effective against other viruses, and animal studies " ...will reveal whether Ebola virus is typical in this regard. " The findings may also be useful in development of an Ebola virus vaccine, as the antibody defines a neutralizing epitope of the viral envelope. " If a potential vaccine did not express this epitope, ie, did not bind the antibody, then that would be seen as a serious deficiency, " Dr. Burton explained in a comment to Reuters Health. A lot of research is taking a " back engineering " approach, he added. That is to say, the antibody structure is used to " ...work back to a molecular shape (effectively a mimic of the epitope) that could act as a vaccine and elicit the antibody, or ones closely similar, when injected. " While the validity of this strategy is not yet established, " ...there are some promising signs, " Dr. Burton said. He also stressed the importance of determining whether neutralizing antibodies can protect animals against Ebola virus challenge. " If they can, then the induction of neutralizing antibodies should be one goal of vaccine design; if not, then vaccinologists would likely be more interested in pursuing cellular responses to the virus. " At this point, it looks as if antibodies may be protective. " Our early data in small animal models are very promising that neutralizing antibodies will be effective against the virus in vivo, " Dr. Burton concluded. J Virol 1999;73:6024-6030. -Westport Newsroom 203 319 2700 -------------------------------------------------------------------------------- Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 14, 1999 Report Share Posted July 14, 1999 Natural Antibody, Recombinant IgG Effectively Neutralize Ebola Virus -------------------------------------------------------------------------------- By Saunders WESTPORT, Jul 06 (Reuters Health) - A neutralizing human antibody to Ebola virus has been identified by a US team of researchers, who also generated a recombinant IgG molecule that may be useful in passive prophylaxis against infection. Dr. Dennis R. Burton, of The Scripps Research Institute in La Jolla, California, used RNA from survivors of a 1995 Ebola virus outbreak in the Congo to construct phage display libraries of monoclonal antibodies. These were panned with Ebola virus antigens--nucleoprotein, envelope glycoprotein, and soluble envelope glycoprotein. The investigators identified seven reacting antibodies. The recombinant fragment (Fab) of one of them, an antibody specific for envelope glycoprotein, " ...neutralized Ebola virus to 50% at 0.4 mcg/mL. " When this Fab was expressed as a whole IgG protein, antiviral activity was improved, with 50% neutralization occurring at a concentration of 0.3 mcg/mL. Dr. Burton and colleagues note that this neutralizing potency " ...is within the range that may lead to protection in passive-immunization studies. " Immunoglobulin concentrations that produce 90% neutralization have been effective against other viruses, and animal studies " ...will reveal whether Ebola virus is typical in this regard. " The findings may also be useful in development of an Ebola virus vaccine, as the antibody defines a neutralizing epitope of the viral envelope. " If a potential vaccine did not express this epitope, ie, did not bind the antibody, then that would be seen as a serious deficiency, " Dr. Burton explained in a comment to Reuters Health. A lot of research is taking a " back engineering " approach, he added. That is to say, the antibody structure is used to " ...work back to a molecular shape (effectively a mimic of the epitope) that could act as a vaccine and elicit the antibody, or ones closely similar, when injected. " While the validity of this strategy is not yet established, " ...there are some promising signs, " Dr. Burton said. He also stressed the importance of determining whether neutralizing antibodies can protect animals against Ebola virus challenge. " If they can, then the induction of neutralizing antibodies should be one goal of vaccine design; if not, then vaccinologists would likely be more interested in pursuing cellular responses to the virus. " At this point, it looks as if antibodies may be protective. " Our early data in small animal models are very promising that neutralizing antibodies will be effective against the virus in vivo, " Dr. Burton concluded. J Virol 1999;73:6024-6030. -Westport Newsroom 203 319 2700 -------------------------------------------------------------------------------- Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 9, 2002 Report Share Posted February 9, 2002 Kay wrote: " I was checked Feb. 7 for CMT and test came back negative but I do have carpeltunnel, I am a hairdresser or stylist however you want to put it. I am so thankful I don`t have it but don`t know if I could be a carrier how would I find that out? " Hello Kay, I know it is a great relief to know that you do not have CMT. You mentioned your uncle did; but is he your uncle on your mother's side of the family or your father's. Do any other relatives have CMT? For my family it came from my maternal grandfather's side of the family. My my passed it along to my older sister (46) and to me (42). We were tested for CMT with an EMG. There is a blood test now for some types of CMT. It could be that the disease " skipped " you. Just keep reading the posts and perhaps more members will respond. Don't stress yourself out over this....since your test came back negative. I've known several people with carpel tunnel, so I'm sure your hands/wrists might bother you being a hairdresser. Be good to yourself and take care. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.